Free Trial
The Rate Lock Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 a Year
Claim MarketBeat All Access Sale Promotion

Canaccord Genuity Group's Rating of Regeneron Pharmaceuticals on 10/28/2026

On October 28, 2026, Canaccord Genuity Group updated its outlook on Regeneron Pharmaceuticals (NASDAQ:REGN) with the action "Boost Price Target", setting a price target of $922.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Canaccord Genuity Group Inc.

DateCompanyAction
10/29/2026
The Middleby Corporation stock logo
MIDD
Middleby
Set Price Target
10/29/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Boost Price Target
10/29/2026
Hudson Technologies, Inc. stock logo
HDSN
Hudson Technologies
Lower Price Target
10/29/2026
ServiceNow, Inc. stock logo
NOW
ServiceNow
Set Price Target
10/29/2026
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Lower Price Target
10/29/2026
MediaAlpha, Inc. stock logo
MAX
MediaAlpha
Boost Price Target
More Ratings From Canaccord Genuity Group Inc.